Dolutegravir/lamivudine/tenofovir disoproxil fumarate - Aurobindo Pharma

Drug Profile

Dolutegravir/lamivudine/tenofovir disoproxil fumarate - Aurobindo Pharma

Latest Information Update: 06 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aurobindo Pharma
  • Class 3-ring heterocyclic compounds; Amides; Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Oxazines; Phosphonic acids; Purines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action HIV integrase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration HIV-1 infections

Most Recent Events

  • 21 Aug 2017 Aurobindo Pharma intends to launch dolutegravir/lamivudine/tenofovir disoproxil fumarate tablets in sub-Saharan Africa in 2018
  • 21 Aug 2017 FDA issues tentative approval to dolutegravir/lamivudine/tenofovir disoproxil fumarate (50 mg/300 mg/300 mg) tablets for the treatment of HIV-1 infections (In adults, In adolescents) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top